Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21704319 | 0.87 | L3MBTL1 (0.67) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL21704471 | 0.83 | ADORA2B (0.58) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL21704331 | 0.83 | ALDH1A1 (0.44) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL21704504 | 0.74 | HSP90AA1 (0.51) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL23204334 | 0.74 | ADORA2B (0.57) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL21704463 | 0.74 | L3MBTL1 (0.64) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL29623115 | 0.73 | ADORA2B (0.62) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL23162758 | 0.73 | ADORA2B (0.62) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL23204167 | 0.70 | ADORA2B (0.57) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A | |
| SCHEMBL23162595 | 0.70 | ADORA2B (0.57) | ADORA2BL3MBTL1ALDH1A1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066413-B2 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2021-07-20 | — | — | US | disclosed |
| US-20200048270-A1 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048270-A1 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ADORA2A, ADORA2B, ADORA3 | ADORA2B 2/4885L3MBTL1 4698/4885ALDH1A1 939/4885 |
| US-11066413-B2 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | ADORA2A, ADORA2B, ADORA3 | ADORA2B 2/4885L3MBTL1 4698/4885ALDH1A1 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.